Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine
Abstract Background There is a clear need for novel approaches to malaria vaccine development. We aimed to develop a genetically attenuated blood-stage vaccine and test its safety, infectivity, and immunogenicity in healthy volunteers. Our approach was to target the gene encoding the knob-associated...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMC
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/74cfc9b904474091b17850c1e5910004 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:74cfc9b904474091b17850c1e5910004 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:74cfc9b904474091b17850c1e59100042021-11-28T12:15:22ZSafety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine10.1186/s12916-021-02150-x1741-7015https://doaj.org/article/74cfc9b904474091b17850c1e59100042021-11-01T00:00:00Zhttps://doi.org/10.1186/s12916-021-02150-xhttps://doaj.org/toc/1741-7015Abstract Background There is a clear need for novel approaches to malaria vaccine development. We aimed to develop a genetically attenuated blood-stage vaccine and test its safety, infectivity, and immunogenicity in healthy volunteers. Our approach was to target the gene encoding the knob-associated histidine-rich protein (KAHRP), which is responsible for the assembly of knob structures at the infected erythrocyte surface. Knobs are required for correct display of the polymorphic adhesion ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1), a key virulence determinant encoded by a repertoire of var genes. Methods The gene encoding KAHRP was deleted from P. falciparum 3D7 and a master cell bank was produced in accordance with Good Manufacturing Practice. Eight malaria naïve males were intravenously inoculated (day 0) with 1800 (2 subjects), 1.8 × 105 (2 subjects), or 3 × 106 viable parasites (4 subjects). Parasitemia was measured using qPCR; immunogenicity was determined using standard assays. Parasites were rescued into culture for in vitro analyses (genome sequencing, cytoadhesion assays, scanning electron microscopy, var gene expression). Results None of the subjects who were administered with 1800 or 1.8 × 105 parasites developed parasitemia; 3/4 subjects administered 3× 106 parasites developed significant parasitemia, first detected on days 13, 18, and 22. One of these three subjects developed symptoms of malaria simultaneously with influenza B (day 17; 14,022 parasites/mL); one subject developed mild symptoms on day 28 (19,956 parasites/mL); and one subject remained asymptomatic up to day 35 (5046 parasites/mL). Parasitemia rapidly cleared with artemether/lumefantrine. Parasitemia induced a parasite-specific antibody and cell-mediated immune response. Parasites cultured ex vivo exhibited genotypic and phenotypic properties similar to inoculated parasites, although the var gene expression profile changed during growth in vivo. Conclusions This study represents the first clinical investigation of a genetically attenuated blood-stage human malaria vaccine. A P. falciparum 3D7 kahrp– strain was tested in vivo and found to be immunogenic but can lead to patent parasitemia at high doses. Trial registration Australian New Zealand Clinical Trials Registry (number: ACTRN12617000824369 ; date: 06 June 2017).Rebecca WebsterSilvana SekuloskiAnand OdedraStephen WoolleyHelen JenningsFiona AmanteKatharine R. TrenholmeJulie HealerAlan F. CowmanEmily M. ErikssonPriyanka SatheJocelyn PeningtonAdam J. BlanchMatthew W. A. DixonLeann TilleyMichael F. DuffyAlister CraigJanet StormJo-Anne ChanKrystal EvansAnthony T. PapenfussLouis SchofieldPaul GriffinBridget E. BarberDean AndrewMichelle J. BoyleFabian de Labastida RiveraChristian EngwerdaJames S. McCarthyBMCarticleMalariaVaccinePlasmodium falciparumGenetically attenuatedKAHRPPfEMP1MedicineRENBMC Medicine, Vol 19, Iss 1, Pp 1-13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Malaria Vaccine Plasmodium falciparum Genetically attenuated KAHRP PfEMP1 Medicine R |
| spellingShingle |
Malaria Vaccine Plasmodium falciparum Genetically attenuated KAHRP PfEMP1 Medicine R Rebecca Webster Silvana Sekuloski Anand Odedra Stephen Woolley Helen Jennings Fiona Amante Katharine R. Trenholme Julie Healer Alan F. Cowman Emily M. Eriksson Priyanka Sathe Jocelyn Penington Adam J. Blanch Matthew W. A. Dixon Leann Tilley Michael F. Duffy Alister Craig Janet Storm Jo-Anne Chan Krystal Evans Anthony T. Papenfuss Louis Schofield Paul Griffin Bridget E. Barber Dean Andrew Michelle J. Boyle Fabian de Labastida Rivera Christian Engwerda James S. McCarthy Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine |
| description |
Abstract Background There is a clear need for novel approaches to malaria vaccine development. We aimed to develop a genetically attenuated blood-stage vaccine and test its safety, infectivity, and immunogenicity in healthy volunteers. Our approach was to target the gene encoding the knob-associated histidine-rich protein (KAHRP), which is responsible for the assembly of knob structures at the infected erythrocyte surface. Knobs are required for correct display of the polymorphic adhesion ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1), a key virulence determinant encoded by a repertoire of var genes. Methods The gene encoding KAHRP was deleted from P. falciparum 3D7 and a master cell bank was produced in accordance with Good Manufacturing Practice. Eight malaria naïve males were intravenously inoculated (day 0) with 1800 (2 subjects), 1.8 × 105 (2 subjects), or 3 × 106 viable parasites (4 subjects). Parasitemia was measured using qPCR; immunogenicity was determined using standard assays. Parasites were rescued into culture for in vitro analyses (genome sequencing, cytoadhesion assays, scanning electron microscopy, var gene expression). Results None of the subjects who were administered with 1800 or 1.8 × 105 parasites developed parasitemia; 3/4 subjects administered 3× 106 parasites developed significant parasitemia, first detected on days 13, 18, and 22. One of these three subjects developed symptoms of malaria simultaneously with influenza B (day 17; 14,022 parasites/mL); one subject developed mild symptoms on day 28 (19,956 parasites/mL); and one subject remained asymptomatic up to day 35 (5046 parasites/mL). Parasitemia rapidly cleared with artemether/lumefantrine. Parasitemia induced a parasite-specific antibody and cell-mediated immune response. Parasites cultured ex vivo exhibited genotypic and phenotypic properties similar to inoculated parasites, although the var gene expression profile changed during growth in vivo. Conclusions This study represents the first clinical investigation of a genetically attenuated blood-stage human malaria vaccine. A P. falciparum 3D7 kahrp– strain was tested in vivo and found to be immunogenic but can lead to patent parasitemia at high doses. Trial registration Australian New Zealand Clinical Trials Registry (number: ACTRN12617000824369 ; date: 06 June 2017). |
| format |
article |
| author |
Rebecca Webster Silvana Sekuloski Anand Odedra Stephen Woolley Helen Jennings Fiona Amante Katharine R. Trenholme Julie Healer Alan F. Cowman Emily M. Eriksson Priyanka Sathe Jocelyn Penington Adam J. Blanch Matthew W. A. Dixon Leann Tilley Michael F. Duffy Alister Craig Janet Storm Jo-Anne Chan Krystal Evans Anthony T. Papenfuss Louis Schofield Paul Griffin Bridget E. Barber Dean Andrew Michelle J. Boyle Fabian de Labastida Rivera Christian Engwerda James S. McCarthy |
| author_facet |
Rebecca Webster Silvana Sekuloski Anand Odedra Stephen Woolley Helen Jennings Fiona Amante Katharine R. Trenholme Julie Healer Alan F. Cowman Emily M. Eriksson Priyanka Sathe Jocelyn Penington Adam J. Blanch Matthew W. A. Dixon Leann Tilley Michael F. Duffy Alister Craig Janet Storm Jo-Anne Chan Krystal Evans Anthony T. Papenfuss Louis Schofield Paul Griffin Bridget E. Barber Dean Andrew Michelle J. Boyle Fabian de Labastida Rivera Christian Engwerda James S. McCarthy |
| author_sort |
Rebecca Webster |
| title |
Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine |
| title_short |
Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine |
| title_full |
Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine |
| title_fullStr |
Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine |
| title_full_unstemmed |
Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine |
| title_sort |
safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine |
| publisher |
BMC |
| publishDate |
2021 |
| url |
https://doaj.org/article/74cfc9b904474091b17850c1e5910004 |
| work_keys_str_mv |
AT rebeccawebster safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT silvanasekuloski safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT anandodedra safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT stephenwoolley safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT helenjennings safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT fionaamante safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT katharinertrenholme safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT juliehealer safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT alanfcowman safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT emilymeriksson safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT priyankasathe safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT jocelynpenington safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT adamjblanch safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT matthewwadixon safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT leanntilley safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT michaelfduffy safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT alistercraig safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT janetstorm safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT joannechan safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT krystalevans safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT anthonytpapenfuss safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT louisschofield safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT paulgriffin safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT bridgetebarber safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT deanandrew safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT michellejboyle safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT fabiandelabastidarivera safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT christianengwerda safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine AT jamessmccarthy safetyinfectivityandimmunogenicityofageneticallyattenuatedbloodstagemalariavaccine |
| _version_ |
1718408083152044032 |